This can enhance CAR T therapy by killing tumor cells, removing IL-7 and IL-15 competition, making them more available to CAR T cells in the absence of endogenous lymphocytes, and, therefore, improving CAR T-cell proliferation and persistence. Here, IL7 is linked to neoplasm.